Patients with hepatitis C genotype 1 who achieved sustained virologic response after direct-acting antiviral treatment had significant improvement or reversal of insulin resistance, according to a recently published study.
“Both experimental and clinical studies have demonstrated that HCV induces [insulin resistance (IR). Moreover, a close correlation between the viral load and IR was observed in genotype 1 infection, indicating a possible direct link between the two conditions,” Luigi E. Adinolfi, MD, from University of Campania, Italy, and colleagues wrote. “Our study demonstrated that HCV patients reaching SVR have a better glycemic control, thus it is possible to hypothesize that clearance of HCV in diabetic patients could improve the glucose homeostasis control.”
The researchers enrolled 68 patients with HCV genotype 1 and advanced fibrosis who underwent DAA therapy with simeprevir and sofosbuvir with ribavirin, ledipasvir and sofosbuvir with ribavirin, or ombitasvir/paritaprevir/ritonavir with dasabuvir and ribavirin. They also enrolled 65 control patients with HCV.